Analysis: Biosimilars Show Comparable Effectiveness to Humira in Psoriasis

Adalimumab biosimilars Amjevita and Imraldi showed similar effectiveness to Humira for the treatment of psoriasis in both new users and patients switching from Humira, according to an analysis of the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).

The study authors looked at data from 11,400 psoriasis patients (60.7% male; mean age; 45.3 years). Two analyses were conducted: a new user cohort (n = 6,133) and a switcher cohort (n = 5,267). New users included 5,416 patients initiating Humira, 382 initiating Amjevita, and 335 initiating Imraldi. Switchers included 3,808 patients continuing Humira, 847 switching to Amjevita, and 612 switching to Imraldi. Primary outcomes included the probability of achieving a Psoriasis Area and Severity Index (PASI) score of 2 or less and a PASI score of 4 or less at 12 months. 

For new users, no significant differences were found between biosimilars and Humira in achieving a PASI score of 2 or less (Amjevita: aOR = 0.98; Imraldi: aOR = 0.83) or a PASI score of 4 or less (Amjevita: aOR = 1.07; Imraldi: aOR = 0.91). Switchers to Amjevita and Imraldi showed no significant differences vs. those continuing Humira in achieving a PASI score of 2 or less (Amjevita: aOR = 1.19; Imraldi: aOR = 0.92) or a PASI score of 4 or less (Amjevita: aOR = 1.32; Imraldi: aOR = 1.00).

"The effectiveness of Amjevita and Imraldi was comparable with that of Humira for both new starters and patients switching to biosimilars from Humira," the authors wrote. 

Source: Phan DB, et al. JAMA Dermatology. 2025. Doi:10.1001/jamadermatol.2025.0055